Skip to main content

Table 2 Antitumor activity grouped by CD8 status (N=48)

From: Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial

Antitumor activity All 10-20% (n=35) > 20% (n=13)
Objective response 39 (81.3, 70.2-92.3) 26 (74.3, 56.7-87.5) 13 (100, 75.3-100)
Best overall response
 Complete response 5 (10.4) 5 (14.3) 0 (0)
 Partial response 34 (70.8) 21 (60.0) 13 (100)
 Stable disease 5 (10.4) 5 (14.3) 0 (0)
 Progressive disease 2 (4.2) 2 (5.7) 0 (0)
 Unknown 2 (4.2)* 2 (5.7) 0 (0)
  1. Data are presented as No. (%, 95% CI) or No. (%)
  2. Responses were assessed in accordance with RECIST version 1.1. Only confirmed responses were included
  3. *Two patients exempted post-baseline efficacy assessments